Prognostic significance of Ki-67 labeling index in papillary thyroid carcinoma

World Journal of Surgery

Volumn 34, Issue 12, 2010, Pages 3015-3021

  Ito, Yasuhiro ^a   Miyauchi, Akira ^a   Kakudo, Kennichi ^b   Hirokawa, Mitsuyoshi ^a   Kobayashi, Kaoru ^a   Miya, Akihiro ^a  

^a KUMA HOSPITAL   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL; THYROID TUMOR;

ADENOCARCINOMA, PAPILLARY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; YOUNG ADULT;

EID: 78651318766     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-010-0746-3     Document Type: Article

References (33)

1. Ito Y, Miyauchi A (2009) Prognostic factors and therapeutic strategies for differentiated carcinoma of the thyroid. Endocr J 56:177-192
2. Ito Y, Tomoda C, Uruno T et al (2005) Ultrasound-detectable and anatomopathologically detectable node metastasis in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg 29:917-920
3. Ito Y, Tomoda C, Uruno T et al (2006) Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 30:780-786 (Pubitemid 43724106)
4. Ito Y, Kakudo K, Hirokawa M et al (2009) Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery 145:100-105
5. Cattoretti G, Becker MH, Key G et al (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin- fixed paraffin sections. J Pathol 168:357-363
6. Wallin G, Backdahl M, Christensson B, Brimelius L, Atter G (1992) Nuclear protein content and Ki-67 immunoreactivity in nonneoplastic and neoplastic thyroid cells. Anal Quant Cytol Histol 14:296-303
7. Basolo F, Pollina L, Fontanini G, Fiore L, Pacini F, Baldanzi A (1997) Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br J Cancer 75:537-541
8. Besnick MB, Schacter P, Finkelstein Y, Kellner Y, Cohen O (1998) Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod Pathol 11:735-739
9. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV (1998) Expression of p27/kip 1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 11:169-174
10. Rickert D, Mitternayer C, Lindenfelser R, Biesterfeld S (2000) MIB-1 immunohistochemistry of follicular adenoma and follicular carcinoma of the thyroid gland. Anal Quant Cytol Histol 22:229-234
11. Mehrotra P, Gonzalez MA, Johnson SJ et al (2006) Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy. Laryngoscope 116:1434-1438
12. Sobin LH, Wittekind CH (eds) (2002) UICC: TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York
13. Ito Y, Uruno T, Takamura Y et al (2005) Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 68:87-96
14. Lim DJ, Baek KH, Lee YS et al (2007) Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid 17:883-888
15. Kjellman P, Wallin G, Hoog A, Auer G, Larsson C, Zadenius J (2003) MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma? Thyroid 13:371-380
16. Siironen P, Louhimo J, Nordling S et al (2005) Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol 26:57-64
17. Sofiadis A, Tani E, Foukakis T et al (2009) Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. Int J Oncol 35:369-374
18. Gunia S, Albrescht K, Koch S et al (2008) Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 26:243-250
19. Preusser M, Heinzi H, Gelpi E et al (2008) Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 53:39-47
20. El AH, Esmail E, Abbas M, Ouf K (2001) MIB-1 index, S-phase fraction, mitotic figure count, and SBR histological grading in invasive breast carcinoma: a comparative study. Breast J 7:106-110
21. Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM (1986) Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 166:209-219
22. Hoyt JW, Gown AM, Kim DK, Berger MS (1995) Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues. J Neurooncol 24:183-189
23. Sullivan RP, Mortimer G, Murschertaigh IO (1993) Cell proliferation in breast tumours: analysis of histological parameters Ki67 and PCNA expression. Ir J Med Sci 162:343-347
24. Pelosi G, Bresaola E, Manfrin E, Rodella S, Schiavon I, Iannucci A (1994) Immunocytochemical detection of cell proliferationrelated antigens in cytologic smears of human malignant neoplasms u sing PC10, reactive with proliferating cell nuclear antigen, and Ki-67. A comparative study. Arch Pathol Lab Med 118:510-516
25. Marais R, Marshall CJ (1996) Control of the ERK MAP kinase cascade by Ras and Raf. In: Parker PJ, Pawson T (eds) Cell signaling. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 101-125
26. Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25-40
27. MacCorkle RA, Tan TH (2005) Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 43:451-461
28. Kim TY, Kim WB, Rhee YS et al (2006) The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 65:364-368
29. Fugazzola L, Peuxeddu E, Avenia N et al (2006) Correlation between B-RAFV600E mutation and clinicopathologic parameters in papillary thyroid carcinoma: data from a multicentric Italia study and review of the literature. Endcr Relat Cancer 13:455-464
30. Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379
31. Lupi C, Glannini R, Ugolini C et al (2007) Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92:4085-4090
32. Nakayama H, Yoshida A, Nakamura Y et al (2007) Clinical significance of BRAF(V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27:3645-3649
33. Ito Y, Yoshida H, Maruo R et al (2009) BRAF mutation in papillary thyroid carcinoma in Japanese population: its lack of correlation with high-risk clinicopathological features and disease- free survival of patients. Endocr J 56:89-97